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Abstract
Background: Whether peripherally inserted central catheters (PICCs) are appropriate as safe and durable venous access devices
(VADs) is still controversial. The aim of this 7-year, prospective cohort study was to compare the incidence rate differences of
catheter-related complications (CRCs) among 4 types of central VADs in cancer patients receiving home parenteral nutrition
(HPN). Methods: We enrolled all adult cancer outpatients who were candidates for HPN and who had a central VAD inserted
during the study period, focusing on the incidence rate of CRCs. Results: We evaluated 854 central VADs (401 PICCs, 137
nontunneled centrally inserted central catheters [CICCs], 118 tunneled-cuffed CICCs, and 198 ports) in 761 patients, for a total of
169,116 catheter-days. Overall, the rate of total CRCs was 1.08/1000 catheter-days. The incidence of catheter-related bloodstream
infections was low (0.29/1000), particularly for PICCs (0.08/1000; P < .001 vs tunneled-cuffed CICCs) and for ports (0.21/1000;
P < .019 vs tunneled-cuffed CICCs). The rates of mechanical complications (0.58/1000) and of catheter-related symptomatic
thrombosis (0.09/1000) were low and similar for PICCs, tunneled-cuffed CICCs, and ports. In terms of duration and removal rate
due to complications, PICCs were like tunneled-cuffed CICCs and ports. Altogether, PICCs had fewer total complications than
tunneled-cuffed CICCs (P < .001), there was no difference in total complications between PICCs and ports. Conclusion: PICCs
had significantly better outcomes than tunneled-cuffed CICCs and were safe and durable as ports. Our extensive, long-term study
suggests that PICCs can be successfully used as safe and long-lasting VADs for HPN in cancer patients. (JPEN J Parenter Enteral
Nutr. 2020;00:1–9)
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Clinical Relevancy Statement
Central venous access devices (VADs) are particularly
needed now in the care of cancer patients since the
emphasis has shifted to the outpatients’ scenario. All
healthcare professionals involved in the choice, insertion,
or management of VADs should know the pros and cons
of the different central VADs. This study demonstrates
that peripherally inserted central catheters (PICCs) can
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be safely used for home parenteral nutrition (HPN) in
cancer outpatients, as they are associated with a low
incidence of catheter-related bloodstream infections,
catheter-related thrombosis, and mechanical complications
(overall complications: 0.69/1000 catheter-days). The main
finding of this study is that PICCs have significantly better
outcomes than tunneled-cuffed centrally inserted central
catheters in regard to being safe and durable as ports. These
findings are clinically relevant for guiding providers in the
proper choice of a safe and long-lasting central VAD in the
adult cancer patient eligible for HPN.
Introduction
A safe and reliable central venous access device (VAD) is
essential for the management of the oncology patient, both
in the initial phases (surgery, radiotherapy, and chemother-
apy) and in the advanced stage (home parenteral nutrition
[HPN]1,2 or palliative care3). At present, the choice of the
type of VAD for HPN in cancer patients mostly depends
on the expected duration of the intravenous treatment, on
the clinical experience of the operator,4 and—to a lesser
degree—on the preference of the patient.
VADs are often classified as short-term, medium-term,
and long-term devices. However, there is not a worldwide
consensus on the interpretation of these terms. Peripherally
inserted central catheters (PICCs) have never been clearly
classified as short-term,medium-term, or long-termVADs.5
Initially, because of lack of clinical data, PICCs were
recommended for dwell times of weeks or months. In the
2009 guidelines of the European Society for Clinical Nu-
trition and Metabolism, PICCs were considered medium-
term VADs, appropriate for HPN of ≤3 months.6 On the
other hand, the 2008 guidelines of the Australasian Society
for Parenteral and Enteral Nutrition considered that PICCs
were also appropriate for longer periods of HPN, ≤12–
18 months.7 Indeed, the Infusion Nurses Society (INS)
suggests that the absolute PICC dwell time is hard to define
and that a PICC may stay in place as long as there are no
complications requiring its removal.8 In the 2011 Standards
of Practice, INS stated the following: “Do not routinely
replace PICCs to prevent catheter-related infections.”9
Though they have been available since the mid-1970s, a
significant clinical experience with PICCs started in North
America about 20 years ago. Several clinical studies demon-
strated the safety and effectiveness of PICCs in home-care
patients10,11; in particular, PICCs were considered appro-
priate as tunneled-cuffed centrally inserted central catheters
(CICCs) and ports for the delivery of HPN.12 Nonetheless,
several reports about HPN in Europe,13,14 Australia,15 and
the US16 published at the beginning of this century have
failed to mention PICCs.
In our hospital, PICCs were not considered appropriate
for HPN until 2008. From June 2008 on, we started to
suggest to patients, oncologists, and VAD providers the
placement of PICCs in cancer patients who were candidates
for HPN, independently from the anticipated need of VAD
duration. In a previous study, we investigated the incidence
of catheter-related complications (CRCs) in cancer patients
receiving HPN and the relationship between CRCs and the
most significant risk factors.17 The aim of this prospective
cohort study was to describe, more closely, the incidence
of CRCs in cancer patients receiving HPN, comparing 4
different types of central VADs used for this purpose.
Methods
In this prospective cohort study, we consecutively enrolled
all adult cancer outpatients who were candidates for HPN
and who had a central VAD inserted during the study
period. The study was carried out for 7 years—from June
1, 2008, through May 31, 2015—in a 1200-bed university
hospital. All patients were followed up from the time of
VAD insertion until VAD removal or until death; the
follow-up study was concluded when the last VAD inserted
during the study period was removed. The ethics committee
approved the study protocol, and written informed consent
was obtained from each patient for VAD insertion, forHPN,
and for participation in the study.
During the study period, 4 different types of central
VADs were inserted: (1) nontunneled, noncuffed PICCs (4F
single-lumen silicone catheters with distal valve [Groshong
PICC, Bard Access Systems, Salt Lake City, UT], 4
and 5F single-lumen polyurethane catheters [Vascu-PICC,
MedComp, Harleysville, PA], and 4 and 5F single-lumen
polyurethane power-injectable catheters [Pro-PICC, Med-
Comp; Synergy, HealthLine, San Francisco, CA]); (2) non-
tunneled CICC (5F single-lumen silicone catheters [Hohn,
Bard Access Systems]); (3) tunneled-cuffed CICC (8F
single-lumen silicone catheters with distal valve [Cuffed
Groshong, Bard Access Systems]); and (4) totally im-
planted, centrally inserted ports (standard- and low-profile
reservoirs, connected to silicone or polyurethane catheters
of different calibers [5.5–8F] [Celsite, BBraun, Melsungen,
Germany; BardPort, Bard Access Systems]).
The choice of the type of VAD for each patient was
primarily based on the preference of the operator, though
the preference of the patient, of the caregiver, or of the
other healthcare professionals was also considered. PICCs
were inserted by specifically trained nurses or surgeons;
the other VADs were inserted by anesthesiologists and
surgeons. The technique of insertion consistently includes
maximal barrier precautions and skin antisepsis with
2% chlorhexidine in alcohol. The appropriate central
position of the catheter tip (close to the cavoatrial junction)
was consistently verified, either intraprocedurally by
intracavitary electrocardiography18 or fluoroscopy or
postprocedurally by chest x-ray. According to guidelines,19
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routine anticoagulation for prevention of catheter-related
thrombosis (CRT) was not adopted. In patients receiving
both HPN and chemotherapy, the VAD was used for both
treatments but never at the same time. The VADs were also
used for blood sampling.
Definitions and diagnosis of local infection and catheter-
related bloodstream infections (CRBSIs) were established
according to the guidelines.9,20 Management of CRBSIs
(by removal and/or ≥10–14 days of systemic antibiotic
treatment plus antibiotic lock therapy, when recommended)
closely followed the guidelines, too.20 CRT was diagnosed
and treated according to guidelines6,19; only symptomatic
CRT was considered (local pain, edema, and signs sug-
gesting venous thrombosis, later confirmed by ultrasound
examination with or without color Doppler). Mechanical
complications were managed according to guidelines.6,8
Causes of VAD removal due to CRCs included infection
of the exit site or of the tunnel; CRBSI with indication
for VAD removal because of failure of or contraindication
to conservative treatment9; CRT associated with catheter
malfunction19; rupture of the external segment of the
catheter, if impossible to repair; complete or partial (>4 cm)
dislocation of nontunneled VADs; dislocation of tunneled-
cuffed CICC due to expulsion of the cuff from the tunnel;
and lumen occlusion resistant to disobstruction.
Our criteria for accepting patients in the HPN program
followed the guideline recommendations for eligibility2 and
included proven and prolonged failure to meet nutrition
requirements by oral or enteral route (no food for >1 week
or <60% of requirement for >1–2 weeks), with potential
risk of early death due to malnutrition rather than to
cancer progression; life expectancy >2 months; Karnofsky
Performance Status (KPS) ≥ 50; adequate control of pain
and other severe symptoms (dyspnea, vomiting); absence
of severe organ dysfunctions; written informed consent
confirming that the patient accepted this modality of nu-
trition support; having a central VAD; approval by the
physician responsible for HPN, as well as the oncologist
and the general practitioner; presence of environmental
conditions compatible withHPN; availability of an in-home
caregiver; and availability of a specifically trained nursing
team dedicated to the patient’s home care, as provided by
the Public Health Service. Exclusion criteria for HPN were
capability to meet the nutrition requirements by oral or
enteral route, KPS < 50, uncontrolled symptoms, severe
organ dysfunctions (heart, respiratory, liver, and renal), lack
of an in-home caregiver, and HPN refusal by the patient.
After starting HPN, all patients were closely monitored
by the physician responsible for HPN (first author) via
regularly scheduled and structured telephone interviews (at
least every 15 days) and by the nursing team and general
practitioner via scheduled home visits (initially, daily for 2–
3 weeks, and then at least every week). Home caregivers
administered HPN only after adequate training. Telephone
assistance was available for each patient, as well as for
the caregivers and the healthcare providers. In 98.4% of
patients, HPN was delivered using standard nutrition bags
that were commercially manufactured and contained amino
acids, electrolytes, glucose, and lipids; nutrition was deliv-
ered for 10–14 h/d (preferentially, overnight). According to
guidelines,2 HPNwas prescribed to provide 25–30 kcal/kg/d
and an amino acid supply of 1–1.5 g/kg/d.Depending on the
daily activity of the patient, the HPN regimen was individu-
ally adjusted tomeet protein, energy, and fluid requirements.
Every 30 days from HPN start (±5 days), an in-hospital
re-evaluation by the HPN physician and by the dietitian,
including a 24-hour food recall, was performed. HPN was
withdrawn in cases of worsening clinical state (onset of
severe organ dysfunction or uncontrolled symptoms, down-
grading of performance status, estimated life expectancy of
hours to days, or patient’s request) and in cases of recovery
of an adequate nutrition intake by the oral route.
Statistical Analysis
In a previous study,17 we found a nearly 40% reduction
(16.9% vs 28.9%) in total complications in the PICC group
compared with the tunneled-cuffed CICC group. Similarly,
we found a 33% reduction (19.4% vs 28.9%) in total compli-
cations in the port group comparedwith the tunneled-cuffed
CICC group. We expected a 4:1 and 2:1 PICC allocation
ratio vs tunneled-cuffed CICCs and ports, respectively.
Assuming a 2-sided significance level of 0.05 and a power
of 80% (α = 0.05; β = 0.2), the minimal sample size was
calculated as 423 VADs.
Qualitative variables were described in terms of fre-
quency and percentage, whereas quantitative variables were
reported as median (interquartile range). The rates of com-
plications were expressed per 1000 catheter-days (incidence
rate) and/or as a percentage of total VADs. Our unit
coordinated the data collection and the computation of
the incidence of CRCs. Complications rates were compared
using Fisher exact or χ2 tests, adjusted for catheter-days.
Incidence rate difference (IRD) and 95% CI referred to the
incidence rate in the PICC group minus that in the tunneled
or port groups. The duration of each VADwas calculated as
the number of days between the date of VAD insertion and
the date of VAD removal or patient death from any cause.
The duration of each VADwas expressed as median (range)
and was compared using the Kruskal-Wallis test, followed
by the Dunn posttest. The level of significance was defined
as a P-value < .05. All analyses were carried out using SPSS
17.0 (SPSS, Inc, an IBM Company, Chicago, IL).
Results
We enrolled 761 consecutive cancer outpatients receiving
HPN. Table 1 shows the main characteristics of the patient
population. During the study period, 475 patients (62%)
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Table 1. Characteristics of Study Population.
No. of patients 761
Female sex, no. (%) 380 (50)
Age, median (IQR), y 64 (57–70)
Age categories, no. (%)
<70 555 (73)
≥70 206 (27)
Actual body weight, median (IQR), kg 57.3 (50.4–65)
BMI, median (IQR) 21 (18.7–23.4)
Weight loss,
a



























Chemotherapy/radiation therapy, no. (%)
No 286 (38)
Yes 475 (62)
HPN duration, median (IQR), d 203 (101–296)
Reason for ending HPN, no. (%)
Clinical worsening 267 (35)
Death 298 (39)
Recovery of oral nutrition 196 (26)
BMI, body mass index; HPN, home parenteral nutrition; IQR,
interquartile range; PG-SGA, Patient-Generated Subjective Global
Assessment.
aIn the last 3 months before HPN.
bModerately malnourished or suspected malnutrition.
cSeverely malnourished.
received anticancer treatments, and 616 patients (81%)
received HPN for >90% of the lifespan of the VAD. We
evaluated 854 central VADs (401 PICCs, 137 nontunneled
CICCs, 118 tunneled-cuffed CICCs, and 198 ports), for a
total of 169,116 catheter-days (Table 2). No patient was lost
at follow-up. Figure 1 depicts the trends in use from 2008 to
2015 for the types of VADs.
Table 2 shows the complications associated with the
4 types of VADs. The incidence of CRBSIs was low
(0.29/1000 catheter-days for all VADs), particularly for
PICCs (0.08/1000; P < .001 vs nontunneled and tunneled
CICCs) and for ports (0.21/1000; P < .001 vs nontunneled
andP< .019 vs tunneled CICCs). Because of CRBSIs, 8 pa-
tients required hospitalization and 1 of them died. The total
days of hospitalization because of CRBSIs were 121, cor-
responding to 0.71 days/1000 catheter-days. Symptomatic
CRT was rare (0.09/1000) and similar for PICCs, tunneled-
cuffed CICCs, and ports. Mechanical complications were
uncommon (0.58/1000 for all VADs), particularly for PICCs
(0.45/1000) and ports (0.34/1000) (P < .001 vs nontunneled
CICCs). Overall, the rate of total CRCs was 1.08/1000
(Table 3).
The overall median duration of the VAD was nearly 6
months; nontunneled CICCs had shorter dwell time than
ports or PICCs (P < .001) and tunneled CICCs (P <
.005) (Table 3). Overall, VADs were removed because of
complications only in 11% of cases. Nontunneled CICCs
had a higher incidence of CRCs and also had higher rate
of removal due to complications, if compared with other
VADs (P < .001). The removal rate due to complications
was similar for PICCs, tunneled-cuffed CICCs, and ports
(Table 3). Table 4 shows the incidence of complications of
PICCs compared with tunneled-cuffed CICCs and ports.
Altogether, PICCs had fewer CRBSIs and fewer total
complications, if compared with tunneled-cuffed CICCs (P
< .001); PICCs and ports had similar rates of complications
(CRBSI, CRT, and mechanical and total complications).
Discussion
Because of the reported complication rates in earlier PICC
experiences, some physicians are still concerned about the
risks potentially associatedwith the use of PICCs in patients
requiring PN.5 Indeed, since the 1990s, several studies have
suggested that the use of PICCs is appropriate for PN
because of their low rates of infections and CRT, with no
significant difference in the rate of these complications
when comparing PICCs and CICCs.21–23 Moureau et al,
in a 2002 analysis of a database with 50,470 outpatients
receiving home infusion for a total of 2.83 million catheter-
days, reported that PICCs—51% of all VADs studied—had
a lower incidence of CRBSIs than ports and tunneled-
cuffed catheters (0.11 vs 0.16 and 0.34/1000 catheter-days,
respectively).10 A systematic review of 200 prospective stud-
ies published between 1966 and 2005 by Maki et al showed
that PICCs had a lower rate of CRBSIs (1/1000 catheter-
days) than tunneled-cuffed CICCs (1.6/1000 catheter-days)
in outpatients.11 In ameta-analysis of 23 studies on≈57,000
patients with VADs, PICCs were less likely to be associated
with central line–associated bloodstream infection
(CLABSI) than other VADs.24 A recent meta-analysis
of comparative studies showed that PICCs were associated
with a significantly lower rate of CRBSIs inHPNpatients, if
compared with tunneled-cuffed catheters; however, analysis
of single-arm studies showed that the rate of CRBSIs was
comparable.25 Moreover, meta-analyses showed a lower or
equivalent rate of CRT with PICC use.25,26
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Table 2. Complications of Central Venous Access Devices (VADs).
PICC Nontunneled Tunneled Port Total
VAD, no. 401 (47.0) 137 (16.0) 118 (13.8) 198 (23.2) 854 (100)
Catheter-days 82,516 25,023 22,840 38,737 169,116
Local infection, no. 6 3 5 7 21






No./1000 catheter-days 0.08 0.84 0.57 0.21 0.29
Venous thrombosis, no. (%) 7 (1.7) 4 (2.9) 2 (1.7) 2 (1.0) 15 (1.8)
No./1000 catheter-days 0.08 0.16 0.09 0.05 0.09
Mechanical complications
Catheter dislocation, no. (%) 19 (4.7) 21 (15.3) 5 (4.2) 0 45 (5.3)
Rupture of external tract, no. (%) 4 (1.0) 3 (2.2) 6 (5.1) NA 13 (1.5)
Lumen occlusion, no. (%) 14 (3.5) 9 (6.6) 4 (3.4) 13 (6.6) 40 (4.7)
Total 37
a





No./1000 catheter-days 0.45 1.32 0.66 0.34 0.58
CICC, centrally inserted central catheters; CRBSI, catheter-related bloodstream infection; NA, not applicable; PICC, peripherally inserted central
catheter.
aP < .001 vs nontunneled CICC.
bP < .001 vs tunneled-cuffed CICC.
cP .019 vs tunneled-cuffed CICC.
dP .022 vs nontunneled CICC.
Table 3. Outcomes of Central Venous Access Devices (VADs).
PICC Nontunneled Tunneled Port Total
VAD, no. 401 (47.0) 137 (16.0) 118 (13.8) 198 (23.2) 854 (100)
Complications, no. (%)
Infectious 13 (3.2) 24 (17.5) 18 (15.3) 15 (7.6) 70 (8.2)
Noninfectious 44 (11.0) 37 (27.0) 17 (14.4) 15 (7.6) 113 (13.2)
Total 57
a





No./1000 catheter-days 0.69 2.44 1.53 0.77 1.08







Causes of removal, no. (%)
VAD complications 19 (5) 53 (39) 14 (12) 8 (4) 94 (11)
End of IV therapy 126 (31) 10 (7) 22 (19) 38 (19) 196 (23)
Death 256 (64) 74 (54) 82 (69) 152 (77) 564 (66)
Removal ratio
e







CICC, centrally inserted central catheters; IV, intravenous; PICC, peripherally inserted central catheter.
aP < .001 vs nontunneled CICC and tunneled-cuffed CICC.
bP .027 vs nontunneled CICC.
cP < .001 vs nontunneled CICC.
dP .005 vs tunneled-cuffed CICC.
eRatio between number of removals because of VAD complications and number of total complications.
In the last decade, many technological innovations have
significantly increased the safety of PICCs (ultrasound-
guided venipuncture, new biomaterials, sutureless devices
for securement, and dedicated vascular teams), whereas new
strategies have successfully minimized the risk of infection
(standardized bundles of evidence-based interventions,
strict policies of hand washing, education of healthcare
operators, use of appropriate skin antisepsis, and use
of antimicrobial lock therapy).4,6,27–31 Nowadays, the
incidence rate of PICC-related complications has changed:
CRBSIs, CRT, and mechanical complications are lower
than those reported in the last 20 years. However, no
randomized clinical trial (RCT) has ever compared
PICCs with tunneled-cuffed CICCs or ports in HPN
patients. In a community-based medical center (adopting
a multimodality bundle for infection prevention), Harnage
has reported for PICCs a CLABSI incidence of 0 episodes
per 1000 catheter-days for 7 years.30 Almost half of patients
in the National Patient Registry for Nutrition Care of the
American Society for Parenteral and Enteral Nutrition
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Figure 1. Venous access devices (VADs): trends in use from June 1, 2008, to May 31, 2015. The figure shows a dramatic increase
in PICC (peripherally inserted central catheter) use.
(ASPEN) were using PICCs, reporting less CLABSIs than
those with ports.32 The percentage use of PICCs is similar
in the Canadian Registry of HPN patients, where PICCs
increased from 21.6% (2005–2008) to 52.9% (2011–2014).33
In recent years, the clinical experience with PICCs
increased also in Europe. Two prospective studies showed
that PICCs were associated with a significantly reduced risk
of CRBSIs and similar duration compared with tunneled-
cuffed CICCs17 or ports34 in cancer patients receiving HPN.
Tourè et al reported lower catheter infection rates for PICCs,
if compared with silicone tunneled-cuffed CICCs (Broviac
catheters) in a prospective study of French HPN patients.35
Bech et al36 and Christensen et al37 retrospectively analyzed
the same data set of Danish HPN patients and found higher
CLABSI rates for PICCs, if compared with tunneled-cuffed
CICCs (Hickman catheters). However, PICCs were usually
inserted when the patient was not able to care for the VAD
or when affected by an acute condition. Conversely, 1
prospective study and a meta-analysis showed that patients
using ports for HPN had a significant increase in CRBSIs
compared with PICCs, whereas no difference between
PICCs and tunneled-cuffed catheters was found.38,39
Nowadays, whether the PICC is an appropriate VAD
for long-term treatment is still a controversial issue. The
ASPEN guidelines have stated that the maximum dwell time
of PICCs is unknown and that they are suitable formedium-
term PN.40 Since the PICC has its exit site on the upper
arm, 1 hand may be considered as inoperative and—as a
consequence self-management of the VAD—may present
some difficulties that require the assistance of a caregiver.7
As a matter of fact, all cancer patients receiving HPN in
our study had ≥1 caregiver. A systematic review of the risk
factors for CRBSIs in patients receiving HPN has showed
that a family caregiver or a nurse aid is not associated to
an increase of infection risk, if compared with complete
autonomy; on the contrary, self-management of the VAD
is associated with an increased risk of CRBSIs compared







































































































































































































































































































































































































































































































































































































reported that the limitation of the upper extremity activity
was absent or minimal in 94% of cancer patients with
PICCs.42 Molloy et al found that most cancer patients held
favorable views toward having a PICC and could adapt well
to PICCs with minimal changes of daily living activities, so
they would recommend a PICC to other patients.43
One of the differences of HPN in patients with benign
underlying disease vs cancer patients is the duration of
HPN, which will be notably shorter (months vs years) in the
latter. Therefore, the notion of “long-term HPN” in cancer
patients may be slightly different and may include PICCs as
a safe and effective VAD. Indeed, during the last 2 decades,
PICCs have been increasingly used for cancer patients, both
for chemotherapy and/or HPN.3,29,43–47 Neoplastic disease,
HPN, and chemotherapy are recognized risk factors for the
development of infection and venous thrombosis in patients
with a central VAD.4,13,17,31,48 Nonetheless, the results of this
study confirmed that, if accurately managed, HPN can be
safely provided in cancer patients, even in an advanced stage,
recording a low incidence of CRCs.
We think that several key elements played a pivotal role to
reduce the occurrence of overallHPN-related complications
in our study: (1) the choice of the proper VAD, resulting
from a cooperative process among patient and caregivers,
nurses, and physicians involved in the care of the patient; (2)
the availability of a knowledgeable and experienced venous
access team; (3) a proper training of patients and caregivers,
along with close monitoring by trained nurses at home; and
(4) a well-established experience and collaboration in HPN
prescription, management, and follow-up of the nutrition
support team.
Likewise, the expected duration of a PICC depends on
several factors: the ratio between catheter diameter and
vein diameter (1:3 ratio), the technique of insertion (use
of ultrasound guidance), the consistent intraprocedural
control of the position of the tip (cavoatrial junction), the
choice of location of the exit site (middle third of the upper
arm), the technique of securing the catheter to the skin (use
of sutureless devices), the patient’s compliance, and, most
importantly, the competence of caregiver and nurse in the
maintenance policies.
Limitations of the Study
First, this was a single-center study carried out by clinical
units with a well-established experience both in HPN and
PICC placement. Also, in our study, we enrolled exclusively
cancer outpatients who are always assisted at home by a
trained caregiver and nurses; therefore, our results may not
be generalizable to other patient populations. Second, the
choice of the type of VAD in each patient was mainly based
on the preference of the operator and/or of the patient;
therefore, there was no randomization of patients to the
different VAD groups, although no significant difference in
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terms of patients’ characteristics potentially associated with
an increased risk of CRCs was found. An RCT is needed
before we can recommend PICCs as the preferred long-term
VAD in cancer patients receiving HPN. Third, this study
did not include a multivariate analysis investigating the
most significant risk factors in each catheter complication.
However, this type of analysis has already been carried out
in our previous study.17 Finally, it is difficult to evaluate
whether the complication rates seen in this study were more
attributable to the nature of the VADs used or more so due
to the wise and judicious choice of type of VAD for each
patient.
Conclusions
To the best of our knowledge, this is the largest prospective
clinical study (761 cancer outpatients, using 854 central
VADs for HPN for a total of >169,000 catheter-days)
comparing the rate of CRCs associated with the use of
different VADs. In summary, our data suggest that (1)
PICCs have lower rates of CRBSIs and total complications
than tunneled-cuffed CICCs, whereas no significant IRDs
of complications vs port were found; (2) PICCs have similar
rates of symptomatic CRT, if compared with tunneled-
cuffed CICCs and ports; (3) PICCs have similar dwell time,
if compared with tunneled-cuffed CICCs and ports; and (4)
PICCs have a removal rate due to complications similar to
tunneled-cuffed CICCs and ports.
Previous meta-analyses, using data based on older prac-
tices, stated that PICCs have a higher risk of CRT and
shorter dwell time than CICCs, leading VAD providers
to limit their choice of catheters. On the contrary, our
extensive, long-term study suggests that PICCs can be suc-
cessfully used as safe and durable VADs for HPN in cancer
patients, without expecting a clinically relevant incidence of
complications or failures.
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